Experienced in PIK3CA-Related Overgrowth Spectrum

Dr. Vamshi K. Rao

Pediatric Neurology | Neurology
225 E Chicago Ave, 
Chicago, IL 
Experienced in PIK3CA-Related Overgrowth Spectrum
225 E Chicago Ave, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Vamshi Rao is a Pediatric Neurologist and a Neurologist in Chicago, Illinois. Dr. Rao is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. His top areas of expertise are Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Spinal Muscular Atrophy (SMA), Spinal Muscular Atrophy Type 1, and Thymectomy.

His clinical research consists of co-authoring 36 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Neurology
Neurology
Licenses
Neurology with Special Qualifications in Neurology in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
View 3 Less Insurance Carriers -

Locations

225 E Chicago Ave, Chicago, IL 60611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Controlled, Open-label, Single-ascending Dose, Phase I/II Study to Investigate the Safety and Tolerability, and Efficacy of Intravenous SGT-001 in Male Adolescents and Children With Duchenne Muscular Dystrophy
A Randomized, Controlled, Open-label, Single-ascending Dose, Phase I/II Study to Investigate the Safety and Tolerability, and Efficacy of Intravenous SGT-001 in Male Adolescents and Children With Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: February 03, 2026
Intervention Type: Genetic
Study Drug: SGT-001 Adeno-Associated Virus Microdystrophin Construct
Study Phase: Phase 1/Phase 2
Journey: A Global, Multicenter, Longitudinal Study of the Natural History of Subjects With Limb Girdle Muscular Dystrophy (LGMD) Type 2E (LGMD2E/R4), Type 2D (LGMD2D/R3), Type 2C (LGMD2C/R5), and Type 2A (LGMD2A/R1)
Journey: A Global, Multicenter, Longitudinal Study of the Natural History of Subjects With Limb Girdle Muscular Dystrophy (LGMD) Type 2E (LGMD2E/R4), Type 2D (LGMD2D/R3), Type 2C (LGMD2C/R5), and Type 2A (LGMD2A/R1)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2025
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy (REACH CDM)
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drug: Tideglusib
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Expanded Access Protocol (EAP) of Idebenone in Patients With Duchenne Muscular Dystrophy
Expanded Access Protocol (EAP) of Idebenone in Patients With Duchenne Muscular Dystrophy
Enrollment Status: No_longer_available
Publish Date: April 21, 2023
Intervention Type: Drug
A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: December 07, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

35 Total Publications

Differences in swallowing efficacy of disease modifying treatment between infants receiving pre-symptomatic and symptomatic administration.
Differences in swallowing efficacy of disease modifying treatment between infants receiving pre-symptomatic and symptomatic administration.
Journal: Orphanet journal of rare diseases
Published: August 21, 2025
Similar Doctors
Experienced in PIK3CA-Related Overgrowth Spectrum
Dr. Andrea C. Pardo
Pediatric Neurology | Neurology
Experienced in PIK3CA-Related Overgrowth Spectrum
Dr. Andrea C. Pardo
Pediatric Neurology | Neurology

Lurie Children's Medical Group Inc.

225 E Chicago Ave, 
Chicago, IL 
 (0.1 miles away)
312-227-6415
Languages Spoken:
English, Spanish
See accepted insurances

Andrea Pardo is a Pediatric Neurologist and a Neurologist in Chicago, Illinois. Dr. Pardo is rated as a Distinguished provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. Her top areas of expertise are Corpus Callosum Agenesis, Seizures, Agyria Pachygyria Polymicrogyria, and Focal or Multifocal Malformations in Neuronal Migration.

Experienced in PIK3CA-Related Overgrowth Spectrum
Dr. Charles J. Marcuccilli
Pediatric Neurology | Pediatrics | Neurology
Experienced in PIK3CA-Related Overgrowth Spectrum
Dr. Charles J. Marcuccilli
Pediatric Neurology | Pediatrics | Neurology

Lurie Children's Medical Group Inc.

225 E Chicago Ave, 
Chicago, IL 
 (0.1 miles away)
312-227-6415
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Charles Marcuccilli is a Pediatric Neurologist and a Pediatrics provider in Chicago, Illinois. Dr. Marcuccilli is rated as an Advanced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. His top areas of expertise are Seizures, Epilepsy, Susac Syndrome, and Fetal Thalidomide Syndrome. Dr. Marcuccilli is currently accepting new patients.

Experienced in PIK3CA-Related Overgrowth Spectrum
Dr. Peter T. Heydemann
Pediatric Neurology | Pediatrics | Neurology
Experienced in PIK3CA-Related Overgrowth Spectrum
Dr. Peter T. Heydemann
Pediatric Neurology | Pediatrics | Neurology

Lurie Children's Medical Group Inc.

1620 W Congress Pkwy, 
Chicago, IL 
 (2.8 miles away)
312-942-3034
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Peter Heydemann is a Pediatric Neurologist and a Pediatrics provider in Chicago, Illinois. Dr. Heydemann is rated as a Distinguished provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. His top areas of expertise are Rett Syndrome, Congenital Toxoplasmosis, Primary Amebic Meningoencephalitis, and Duchenne Muscular Dystrophy. Dr. Heydemann is currently accepting new patients in some locations.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rao's expertise for a condition
ConditionClose
View All 18 Advanced Conditions
View All 79 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile